XTX Topco Ltd acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 67,286 shares of the company's stock, valued at approximately $957,000.
A number of other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after buying an additional 859 shares during the period. BNP Paribas Financial Markets lifted its holdings in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after buying an additional 2,596 shares in the last quarter. Smithfield Trust Co grew its stake in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical in the third quarter worth about $52,000. Finally, Headlands Technologies LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter valued at approximately $59,000. Hedge funds and other institutional investors own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Up 0.8 %
Shares of Takeda Pharmaceutical stock traded up $0.10 on Wednesday, hitting $13.57. 2,134,658 shares of the company's stock traded hands, compared to its average volume of 1,837,590. The stock has a market cap of $43.16 billion, a P/E ratio of 23.45, a PEG ratio of 0.25 and a beta of 0.51. The firm's 50-day moving average is $13.86 and its 200 day moving average is $13.88. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08.
Takeda Pharmaceutical Company Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
